NCT05603195View on ClinicalTrials.gov

A Trial to Learn if Single Ascending Intravenous (IV) Doses of REGN7508 Are Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 12, 2023

Primary Completion Date

September 17, 2024

Study Completion Date

September 17, 2024

Conditions
Healthy Volunteer
Interventions
DRUG

REGN7508 (IV)

Administered sequential, ascending single intravenous (IV) dose

DRUG

REGN7508 (SC)

Administered sequential, ascending single subcutaneous (SC) dose

DRUG

Matching Placebo (IV)

Administered sequential, ascending single intravenous (IV) dose

DRUG

Matching Placebo (SC)

Administered sequential, ascending single subcutaneous (SC) dose

Trial Locations (1)

LS2 9LH

Labcorp Clinical Research Unit, Leeds

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY